LONDON, Feb 28 (Reuters) - The top management of Antisoma (ASM.L) (ASM.L) stepped down on Monday as the British cancer specialist cut its operations following the failure of its two leading drug candidates. The company’s leukaemia drug candidate AS1413 failed in a final-stage trial in January, delivering a second blow after the failure of a lung cancer drug, its biggest hope, in March 2010.
